Sebastien Benzekry
Overview
Explore the profile of Sebastien Benzekry including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
45
Citations
649
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nguyen Phuong L, Salas S, Benzekry S
JCO Clin Cancer Inform
. 2025 Feb;
9:e2400224.
PMID: 40020203
Purpose: Liquid biopsy, specifically circulating cell-free DNA (cfDNA), has emerged as a powerful tool for cancer early diagnosis, prognosis, and treatment monitoring over a wide range of cancer types. Computational...
2.
Atsou K, Auperin A, Guigay J, Salas S, Benzekry S
CPT Pharmacometrics Syst Pharmacol
. 2024 Dec;
PMID: 39722558
We employed a mechanistic learning approach, integrating on-treatment tumor kinetics (TK) modeling with various machine learning (ML) models to address the challenge of predicting post-progression survival (PPS)-the duration from the...
3.
Daumas A, Bigarre C, Boucekine M, Zaccariotto A, Kaeppelin B, Mogenet A, et al.
Cancers (Basel)
. 2024 Dec;
16(23).
PMID: 39682307
Background: Prophylactic cranial irradiation (PCI) is recommended to decrease the incidence of brain metastases (BM) in extensive-stage small-cell lung cancer (ESSCLC) without BM after response to chemotherapy. However, PCI is...
4.
Shi Y, McKenery A, Dolan M, Mastri M, Hill J, Dommer A, et al.
EMBO Rep
. 2024 Dec;
26(2):521-559.
PMID: 39663510
Therapeutic inhibition of programmed cell death ligand (PD-L1) is linked to alterations in interferon (IFN) signaling. Since IFN-regulated intracellular signaling can control extracellular secretory programs in tumors to modulate immunity,...
5.
Benzekry S, Karlsen M, Bigarre C, El Kaoutari A, Gomes B, Stern M, et al.
Clin Pharmacol Ther
. 2024 Jul;
116(4):1110-1120.
PMID: 39001619
Existing survival prediction models rely only on baseline or tumor kinetics data and lack machine learning integration. We introduce a novel kinetics-machine learning (kML) model that integrates baseline markers, tumor...
6.
Dolan M, Shi Y, Mastri M, Long M, McKenery A, Hill J, et al.
Mol Cancer Ther
. 2024 Jun;
:OF1-OF20.
PMID: 38896060
Tyrosine kinase inhibitors (TKIs) that block the vascular endothelial growth factor receptors (VEGFRs) not only disrupt tumor angiogenesis but also have many unexpected side effects that impact tumor cells directly....
7.
Benzekry S, Mastri M, Nicolo C, Ebos J
PLoS Comput Biol
. 2024 May;
20(5):e1012088.
PMID: 38701089
Clinical trials involving systemic neoadjuvant treatments in breast cancer aim to shrink tumors before surgery while simultaneously allowing for controlled evaluation of biomarkers, toxicity, and suppression of distant (occult) metastatic...
8.
Dolan M, Shi Y, Mastri M, Long M, McKenery A, Hill J, et al.
Mol Cancer Ther
. 2024 May;
PMID: 38690835
Tyrosine kinase inhibitors (TKIs) that block the vascular endothelial growth factor receptors (VEGFRs) disrupt tumor angiogenesis but also have many unexpected side-effects that impact tumor cells directly. This includes the...
9.
Benzekry S, Schlicke P, Mogenet A, Greillier L, Tomasini P, Simon E
Clin Exp Metastasis
. 2023 Dec;
41(1):55-68.
PMID: 38117432
Intracranial progression after curative treatment of early-stage non-small cell lung cancer (NSCLC) occurs from 10 to 50% and is difficult to manage, given the heterogeneity of clinical presentations and the...
10.
Pradeu T, Daignan-Fornier B, Ewald A, Germain P, Okasha S, Plutynski A, et al.
Biol Rev Camb Philos Soc
. 2023 May;
98(5):1668-1686.
PMID: 37157910
Cancers rely on multiple, heterogeneous processes at different scales, pertaining to many biomedical fields. Therefore, understanding cancer is necessarily an interdisciplinary task that requires placing specialised experimental and clinical research...